Dublin, Ireland-based Endo International plc ENDP is a specialty pharmaceutical company focused on branded and generic pharmaceuticals and devices. The company has several products including Lidoderm, Opana ER, Voltaren Gel, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo’s track record has been pretty impressive with the company beating estimates in three of the last four quarters with an average earnings surprise of 0.06%.
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo’s fourth-quarter 20Array5 earnings surpassed expectations. The company reported EPS of $Array.36 while our consensus called for EPS of $Array.27.
Revenues: Endo posted revenues of $Array.07 billion in line with expectations.
Key Stats: In the fourth quarter of 20Array5, both U.S. Branded Pharmaceuticals and U.S. Generic Pharmaceuticals continued to perform well. Along with its results, the company announced that that it will wind down ASTORA Women's Health (previously known as American Medical Systems’ Women's Health) business operations by Mar 3Array, 20Array6.
20Array6 Guidance: For 20Array6, Endo expects revenues in the range of $4.32 billion to $4.52 billion. The Zacks Consensus Estimate for revenues is currently $4.66 billion. The company updated earnings guidance for 20Array6. It expects earnings per share in the range of $5.85 to $6.20 (old guidance: $5.85 to $6.Array5 per share) in 20Array6. The Zacks Consensus Estimate for earnings is $5.98.
Check back later for our full write up on this Endo earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment